KR101794929B1 - Composition comprising Galla Rhois extract for preventing or treating constipation - Google Patents

Abstract

The present invention relates to a composition comprising a Galla rhois extract as an active ingredient for preventing or treating constipation. The Galla rhois extract according to the present invention increases the number of defecation and the weight of excrement, increases the water content in excrement to ease defecation, increases the thickness of the mucous membrane and muscle, and increases secretion of the mucus to improve intestinal functions and alleviate constipation, thereby being usefully used for preventing or treating constipation.

Description

[0001] The present invention relates to a composition for preventing or treating constipation,

The present invention relates to a composition for preventing or treating constipation comprising an extract of Galla Rhois as an active ingredient.

Recently, people are complaining of constipation due to diverse factors such as lack of dietary fiber and industrialization stress due to increase of intake of meat and instant food due to westernization of dietary habits. Constipation is defined as constipation when it is medically less than 3 bowel movements a week or when the bowel movement is 30g or less per day. Under normal conditions, it is excreted in the stool 24 hours after ingestion of food. However, people with constipation see the stools every few days or even if they see it every day, resulting in a longer stay in the intestinal tract of the resulting food. The causes of constipation include a decrease in the intestinal motility caused by eating breakfast, a lack of dietary fiber due to westernization of dietary life, a decrease in basic physical strength and abdominal strength due to lack of exercise, dieting, drug addiction due to excessive use of drugs, have.

Constipation, which is said to be the source of all diseases from ancient times, has no appetite and is not only in a state where the abdomen is always bloated, but also toxins of the unexcited side are absorbed into the blood through the intestines, thereby promoting aging of the skin and causing headache, acne, skin rash And when constipation is severe, it breaks the dentition and escapes the dentition when it is defecated, and it causes the hemorrhoids by the toxin in the shift. If constipation persists, cholesterol or fat that should be excreted outside the body may remain in the body, which may lead to arteriosclerosis or gallstone disease. Furthermore, hypertension and cardiac hypertrophy may be exacerbated by heart disease. In addition, stroke, immunodeficiency, vision disorders, and mental illness (depression), such as a variety of serious secondary causes of the disease, so constipation is an important disease can be an active prevention and treatment.

To date, various medicines and functional foods for constipation treatment and improvement have been marketed. However, most of the medicines use stimulant medicines containing anthraquinone derivatives such as Senna and Rhubarb to treat side effects such as abdominal pain and diarrhea, And functional foods are not scientifically proved to be effective enough to solve the fundamental problem of constipation improvement, and thus the reliability of the product is deteriorating.

On the other hand, Galla Rhois is an insect house which is made by insect parasitic on the leaves of rhus javanica L. (Rhus javanica L.) and it is also called as anchovy and white chestnut. 50 to 70% Galactanines such as gallic acid, pentagalloyl glucose and the like have been found to be major components.

The process of generating the insect house is as follows. Late September A female insect winged with a hole in the insect house gave birth to a midwife (Minum versicatum, M. trichomane) with a chimpanzee. The chimpanzee sucked the juice of the cetacean, . It becomes a pupa in the spring of the following year, and comes out in the pupa of late April and becomes a female worm with a wing. The female worms give birth to female wingless female wingless worms on the branches of the rhusi after mating and die. Wingless worms are transferred to young leaves and parasitized, and the house of insects grows. At that time, the size is five times the original size, so it is said that it is called obi. Before the early autumn bug leaves, it picks up the insect house, steam it in the steam, kills the insect, and dries.

The pharmacological effects of diarrhea include diarrhea, diarrhea, hemorrhage, hemorrhage, diarrhea due to ulcerative colitis, radioactive rectalitis, oil well, pulmonary tuberculosis, , Premature ejaculation, oozing (啼.), And seasonal influenza in autumn, but the effect of improving constipation has not been disclosed at all.

The inventors of the present invention have been studying a substance having a constipation-improving effect, and found that the extract of the rhizomes increases the number and weight of the stool, increases the water content in the stomach to soften the bowel, increases the mucous membrane and muscle thickness, To improve the intestinal function, thereby improving the constipation. Thus, the present invention has been completed.

It is an object of the present invention to provide a composition for the prevention or treatment of constipation comprising an extract of Opuntia as an active ingredient.

For this purpose, the present invention provides a pharmaceutical composition for the prevention or treatment of constipation, comprising an opioid extract as an active ingredient.

In addition, the present invention provides a food composition for preventing or ameliorating constipation, comprising an opioid extract as an active ingredient.

The rhizome extract according to the present invention improves constipation by increasing the number and weight of stools of the stomach, increasing the water content in the stomach to soften the stool, increasing the mucous membrane and muscle thickness, increasing mucus secretion, It can be effectively used for preventing or treating constipation.

FIG. 1 is a graph showing the results of performing absorbance, DPPH radical suppressing activity, and NMR analysis for analyzing components of the extract of Opuntia ficus-indica according to the present invention.
FIG. 2 is a graph showing the results of staining of H & E and Alcian blue, followed by observation with an optical microscope, of an animal model treated with the extract of Opuntia ficus-indica according to the present invention.
FIG. 3 is a graph showing the results of measuring the expression levels of mAChR M2 and M3 after extracting the large intestine of an animal model treated with the extract of Opuntia ficus-indica according to the present invention.
FIG. 4 is a graph showing the results of measuring the expression levels of pPKC and pPI3K after extracting the large intestine of an animal model treated with the extract of Opuntia ficus-indica according to the present invention.
FIG. 5 is a graph showing the results of measuring the expression levels of Gα and IP3 after extracting the large intestine from an animal model treated with the extract of Opuntia ficus-indica according to the present invention.

The present invention provides a composition for preventing or treating constipation, which comprises an extract of Galla Rhois as an active ingredient.

The compositions of the present invention include pharmaceutical compositions, food compositions.

Hereinafter, the present invention will be described in detail.

The crude extract of the present invention, which is an active ingredient of the present invention, can be obtained by extracting and isolating from nature using an extraction and separation method known in the art, and the 'extract' defined in the present invention can be extracted Crude extract, polar solvent-soluble extract, or non-polar solvent-soluble extract.

As a suitable solvent for extracting the extract from the dwarf, any of water or a pharmaceutically acceptable organic solvent may be used. Examples of the solvent include alcohols having 1 to 4 carbon atoms such as purified water, methanol, ethanol, propanol, isopropanol, and butanol, acetone, ether various solvents such as ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane and cyclohexane may be used alone or as a mixture of two or more thereof. And preferably water or an alcohol having 1 to 4 carbon atoms, and more preferably water.

Examples of the extraction method include hot water extraction, cold extraction, reflux cooling, solvent extraction, steam distillation, ultrasonic extraction, elution, and compression. The desired extract may further be subjected to a conventional fractionation process or may be purified using a conventional purification method.

For example, the crude extract, which is an active ingredient of the composition of the present invention, can be prepared into a powdery state by an additional process such as vacuum distillation, freeze-drying, or spray drying. In addition, the primary extract can be further purified into a further purified fraction using various chromatographies such as silica gel column chromatography, thin layer chromatography, high performance liquid chromatography and the like Can be obtained.

Therefore, the opiate extract used in the present invention is a concept including all the extracts, fractions and tablets obtained in each step of extraction, fractionation or purification, their diluted solution, concentrate or dried product.

The above-mentioned obtusa extract increases the number of bowel movements and weight of the bowel, increases moisture content in the bowel, and softens bowel movements.

In addition, the extract may be used as a pharmaceutical composition or food composition for preventing, ameliorating or treating constipation by increasing the thickness of mucous membrane and muscle and increasing mucus secretion to improve intestinal function.

The constipation of the present invention may include constipation caused by various causes. Concretely, transient constipation, which is a major cause of overeating or stress, diastolic or rectal constipation caused by lack of exercise or abdominal discomfort due to overwork, constipation due to exercise, And constrictive constipation that occurs because movement of the large intestine is too strong to interfere with passage of the sides.

In addition, the constipation of the present invention may include constipation by the drug. Examples of the medicaments which can cause constipation include calcium channel blockers, anticholinergic drugs, analgesics, antidepressants, antihistamines, antispasmodics, anticonvulsants, aluminum-containing antacids, iron preparations and the like. Lt; / RTI > constipation.

In one embodiment of the present invention, loperamide (loperamide), an anti-diarrhea drug, was administered to an animal model that caused constipation.

The composition of the present invention may further contain at least one known active ingredient having an effect of improving constipation, together with the above extract of Opium hygroscopy.

The compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions. In addition, it can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, oral preparations such as syrups and aerosols, external preparations, suppositories and sterilized injection solutions according to a conventional method. Suitable formulations known in the art are preferably those as disclosed in Remington ' s Pharmaceutical Science, recently, Mack Publishing Company, Easton PA. Examples of carriers, excipients and diluents which may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. When the composition is formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, Gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The term "administering" as used herein is meant to provide any desired composition of the invention to a subject in any suitable manner.

The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. For a desired effect, the daily dose of the extract of the present invention may be administered in an amount of 250 mg / kg or more per day, or may be administered once a day or divided into several times.

The pharmaceutical composition of the present invention may be administered to a subject in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.

The composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers for the purpose of improving constipation.

In the present invention, the term "food" refers to a food having a biological control function such as prevention and improvement of disease, bio-defense, immunity, recovery after disease, suppression of aging and the like.

The food composition of the present invention can be added to a health functional food for the purpose of preventing or improving constipation. When the extract according to the present invention is used as a food additive, the extract can be directly added or used together with other food or food ingredients, and can be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). Generally, in the production of a food or beverage, the rhizome extract of the present invention is added in an amount of 15% by weight or less, preferably 10% by weight or less, based on the raw material. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.

There is no particular limitation on the kind of the food. Examples of the foods to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The natural carbohydrates may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, natural sweeteners such as dextrin and cyclodextrin, synthetic sweeteners such as saccharine and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 10 g, preferably about 0.01 to 0.1 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, A carbonating agent used in a carbonated beverage, and the like. In addition, the composition of the present invention may comprise flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Further, the present invention provides a composition for improving intestinal function, comprising a rhizome extract as an active ingredient.

In one embodiment of the present invention, the composition can ameliorate or prevent constipation by improving bowel function.

Hereinafter, preferred embodiments and examples of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples and preparative examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the examples and preparation examples.

Example  1. Preparation of horseradish extract

Galla Rhois harvested from the Hongcheon area during October 2013, washed and dried at 60 ° C. The dried dumbbell sample was uniformly pulverized, and then 10 times of distilled water was added thereto, followed by extraction at 90 ° C for 9 hours using a circulation extractor. Thereafter, the extract was filtered at 0.4 μm, and then vacuum evaporation and freeze-drying were performed to prepare a sample of Avalanche Extract.

Example  2. Analysis of Composition of Rhizoma Extract

In order to confirm the active ingredient of the extract, the absorbance of the extract obtained in Example 1 was measured, and the results are shown in FIG. 1A.

As shown in FIG. 1A, gallic acid, gallotannin and methyl gallate were identified as effective components of the extract of Opuntia ficus-indica extract, which is an active ingredient of Opuntia ficus-indica extract, and galactan, galantanine and methyl gallate Showed maximum absorption wavelengths at 212/257 nm, 213/278 nm and 214/268 nm, respectively.

In addition, HPLC analysis of the rhizome extract was performed. For the HPLC analysis, PDA UV-vis detector and Summit Dual-Gradient HPLC System (Dionex, USA) from Korea Bio-IT Foundry Busan Center were used. The separation was performed on YMC-Triart C18 column -5 mm / 12 nm, 150 mm x 4.6 mm ID). The mobile phase solvent consisted of solvent A (0.4% formic acid in water) and solvent B (acetonitrile) and the mobile phase gradient conditions were: 0-5 min, 10% B; 5-6 minutes, 10-15% B; 6-40 minutes, 15% B; 40-41 min, 15-30% B; 41-50 min, 30% B; 50-55 min, 30-10% B; 55-60 min, 10% B. At this time, the injection volume was 5 ml of the whole loop injection, the flow rate was 0.8 ml / min, and the detection was performed at 280 nm, and the results are shown in FIG.

As shown in Fig. 1B, the presence of gallic acid, galactanine and methyl gallate was confirmed as an effective ingredient of the extract of Opuntia ficus-indica, an effective ingredient of the Opuntia ficus-indica extract.

In addition, DPPH radical scavenging activity analysis of the rhizome extract was carried out. Specifically, a mixture of 100 μL of 95% EtOH solution or 100 μL of 0.1 mM DPPH in 95% EtOH solution was dissolved in 50% ethanol solution and incubated at room temperature for 30 minutes. Then, Absorbance was measured at 517 nm using a Versa-max plate reader (Molecular Devices, Sunnyvale, Calif., USA) and the results are shown in FIG.

As shown in Fig. 1 (c), DPPH radical scavenging activity of the extract of Opuntia mushroom was very high, indicating that it exhibited a high antioxidative activity.

Example  3. Experimental animal breeding and empirical formula

Seven weeks old male Sprague Dawley (SD) rats were purchased and used for breeding at a temperature of 23 ± 2 ° C and a humidity of 50 ± 10% for 12 hours. The experimental animals were purified for 1 week after purchase, and then 6 animals were placed per group, and the experimental groups were classified into 7 groups. The experimental group was divided into two groups: normal control (NO), gigantoprine (GEGR) (1000 ㎎ / ㎏), loperamide (Vehicle) (4 ㎎ / ㎏), rofemide + (HiGEGR) and a positive control group (BS), respectively, compared with the control group (LoGEGR), rofemide + medium concentration group (500 ㎎ / ㎏) (MiGEGR) . As a positive control, Vikogreen (Kolon Pharmaceuticals Inc., Gyenggido, Korea), which is known as a constipation treatment agent, was used. Lipelamide (Sigma, St. Louis, Mo., USA) was administered subcutaneously at 9 o'clock and 6 o'clock for 3 days to all patients except for the normal group. Each sample was orally administered at 9:00 am on the first day and euthanized at 9:00 am on the fifth day.

Experimental Example  1. Weight, feed intake and Quantity of water  Measure

Each of the experimental groups of Example 3 was treated with looperamide, and the body weight, feed intake and the amount of insulin were measured daily at 10 am. The results are shown in Table 1 below.

No GEGR Rofemide Vehicle LoGEGR MiGEGR HiGEGR BS Weight (g) 288 ± 2.9 292 ± 2.2 293 ± 4.4 287 ± 2.0 287 ± 3.4 292 ± 2.9 289 ± 2.3 Feed intake (g / day) 26.9 ± 1.8 28.2 ± 2.3 27.6 ± 3.1 25.1 ± 2.5 26.5 ± 2.8 27.3 ± 2.1 25.2 + 1.7 Amount of water (ml) 25.1 ± 2.0 26.2 ± 2.1 26.4 ± 2.3 24.6 ± 1.8 23.9 ± 3.1 25.1 ± 2.6 27.0 + 1.7

As shown in Table 1, the feed intake and the amount of insulin during the experimental period showed a tendency that the feed intake of the vehicle causing the constipation to rofeamid was slightly lower than that of the GEGR administered group, , And there was no statistically significant difference between the groups in terms of volume and weight

Experimental Example  2. Number of sides and variable weight measurement

For each of the experimental groups of Example 3, after 3 days from the start of administration of ropelamide, the bedding and sides of the cage were cleanly cleaned. After 24 hours, the sides were collected and the number of sides and the weight of the sides were measured. Respectively.

No GEGR Rofemide Vehicle LoGEGR MiGEGR HiGEGR BS Number of sides (ea) 40.3 ± 1.5 42.8 ± 1.9 29.7 ± 1.7 ^a 33.5 ± 2.8 ^a 43.0 ± 2.0 ^b 52.3 ± 1.2 ^b 50.8 ± 2.3 ^b Variable weight (g) 7.7 ± 0.3 8.0 ± 0.4 3.2 ± 0.2 ^a 4.0 ± 0.5 ^{a, b} 7.3 ± 0.2 ^b 8.3 ± 0.2 ^b 8.6 ± 0.3 ^b

(a, P < 0.05, b, P < 0.05,

The number of stools was decreased from 40.3 ± 1.5 in the normal control group to 29.7 ± 1.7 in the vehicle alone group and was found to be 50.8 ± 2.3 in the positive control group And it was confirmed that the induction of constipation by the pyramid was suppressed by the open circuit. In addition, the number of stools tended to increase depending on the concentration of Rhus verniciflua extract, and the number of stools treated with ropheramide + high concentration of Rhus verniciflua extract (HiGEGR) was higher than that of BS, It was confirmed that Rhus verniciflua extract relaxes.

(LoGEGR, MiGEGR, HiGEGR) in the control group.

Experimental Example  3. Intestine  Measuring secretion effect of mucus

For each experimental group of Example 3, both sides of the colon from the posterior cecum to the rectum were excised. The extracted large intestine was fixed with 10% formaldehyde, subjected to a tissue treatment process, and embedded in paraffin to prepare a slice with a thickness of 4 μm. Thereafter, the cells were stained with H & E and Alcian blue (pH 2.5) and observed with an optical microscope. The results are shown in FIG.

As shown in FIG. 2, mucus tended to decrease in the roferamide-treated group compared to the normal control group. On the other hand, positive control group was found to increase the amount of mucin to be stained, and that of mucus extract group was increased by concentration.

Experimental Example  4. Measurement of thickness of mucosa, muscle and flat luminal surface

For each experimental group of Example 3, both sides of the colon from the posterior cecum to the rectum were excised. The extracted large intestine was fixed with 10% formaldehyde, subjected to a tissue treatment process, and embedded in paraffin to prepare a slice with a thickness of 4 μm. The thickness of the mucosa, muscle and flat luminal surface was then measured and the results are shown in Table 3 below.

No GEGR Rofemide Vehicle LoGEGR MiGEGR HiGEGR BS Mucous membrane thickness (mm) 496.4 ± 3.8 487.6 ± 2.3 146.3 ± 2.1 ^a 152.5 + 1.7 ^a 245.6 ± 1.8 ^{a, b} 325.2 ± 2.3 ^{a, b} 458.8 ± 1.5 ^b Muscle Thickness (mm) 95.1 ± 3.3 92.2 ± 2.4 68.8 ± 2.6 ^a 78.3 ± 2.1 ^a 71.2 ± 1.3 ^{a, b} 85.6 ± 1.0 ^{a, b} 94.1 ± 1.6 ^b Thickness of flat lumen surface (mm) 58.8 ± 2.4 59.9 ± 1.8 23.5 ± 1.1 ^a 22.9 ± 2.6 ^a 29.8 ± 1.5 ^{a, b} 42.3 ± 2.4 ^{a, b} 48.5 ± 2.2 ^{a, b}

As shown in Table 3, the thickness of mucous membrane, muscle and flat luminal surface showed a tendency to decrease in rofemide alone group (vehicle) compared to normal control group (NO), and regained in positive control group (BS). In addition, it was confirmed that the thickness of mucous membrane, muscle and flat luminal surface was significantly increased depending on the concentration of Rhus verniciflua extract.

Experimental Example  5. Measurement of number of goblet cells and crypt

For each experimental group of Example 3, both sides of the colon from the posterior cecum to the rectum were excised. The extracted large intestine was fixed with 10% formaldehyde, subjected to a tissue treatment process, and embedded in paraffin to prepare a slice with a thickness of 4 μm. Then, the number of goblet cells and crypts of lieberkhns, which are mucous preparation cells, was measured in the above section, and the results are shown in Table 4 below.

No GEGR Rofemide Vehicle LoGEGR MiGEGR HiGEGR BS Number of goblet cells (ea) 457.3 ± 21.4 468.1 ± 30.2 271.7 ±
18.3 ^a 299.4 ± 25.8 ^a 388.1 ± 35.1 ^{a, b} 402.1 ± 30.8 ^{a, b} 486.7 ± 31.9 ^b Number of crypts of lieberkuhn (ea)  51.1 ± 1.8  53.3 ± 0.5 23.5 ± 2.0 ^a 24.8 ± 1.2 ^a 39.4 ± 2.3 ^{a, b} 45.2 ± 1.8 ^{a, b} 49.8 ± 1.1 ^b

As shown in Table 4, the number of reperfusion cells and crypts tended to decrease in the rofemide alone group compared to the normal control group (NO), and recovered again in the positive control group (BS). In addition, it was confirmed that the number of goblet cells and crypts was significantly increased in a dose dependent manner.

Experimental Example  6. mAChR ( Muskarine Castle  Acetylcholine receptor)

For each experimental group of Example 3, both sides of the colon from the posterior cecum to the rectum were excised. RNA was extracted and RT-PCR was performed to measure the expression level of mAChR (muscarinic acetylcholine receptor) in the extracted large bowel, and the results are shown in FIG.

As shown in FIG. 3, the expression of mAChR tended to decrease in the rofemide alone group (vehicle) compared to the normal control group (NO), and regained in the positive control group (BS). In addition, it was confirmed that the concentration of Rhus verniciflua extract was significantly increased depending on the concentration.

Experimental Example  7. PKC  And PI3K Of expression level

For each experimental group of Example 3, both sides of the colon from the posterior cecum to the rectum were excised. In order to measure the expression levels of pPKC and pPI3K in the extracted large intestine, proteins were extracted and subjected to Western blotting. The results are shown in FIG.

As shown in Fig. 4, the expression of pPKC tended to decrease in the rofemide alone group (vehicle) compared to the normal control group (NO), and regained in the positive control group (BS). In addition, it was confirmed that the concentration of Rhus verniciflua extract was significantly increased depending on the concentration.

On the other hand, the expression of pPI3K was high in rofemide alone group and in positive control group (BS).

Experimental Example  8. Ga and IP3  Measurement of expression level

For each experimental group of Example 3, both sides of the colon from the posterior cecum to the rectum were excised. Proteins were extracted and Western blot was performed to measure the expression level of Gα in the extracted large intestine. Absorbance was measured using an IP3 assay kit to measure the expression level of IP3. The results are shown in FIG. 5 .

As shown in FIG. 5, the expression of Gα was increased in rofemide alone group (vehicle) compared to the normal control group (NO), and a slight decrease was observed in the group administered with the positive control (BS)

On the other hand, the expression of IP3 decreased in the rofemide alone group (vehicle) compared to the normal control group (NO) and regained in the positive control group (BS). In addition, it was confirmed that the concentration of Rhus verniciflua extract was significantly increased depending on the concentration.

As described above, the rhizome extract of the present invention increases the number of bowel movements and weight, improves the bowel function by increasing moisture content in the bowel, enhances mucous membrane and muscle thickness, and increases mucous secretion, The results of this study are as follows.

Hereinafter, a pharmaceutical composition and a pharmaceutical composition for preventing or treating constipation containing the extract of Opuntia ficus, according to the present invention, will be described, but the present invention is not limited thereto but specifically described.

Formulation Example 1. Preparation of pharmaceutical preparations

1-1. Sanje  Produce

Lucie extract 20 mg

Lactose 100 mg

Talc 10 mg

The above components are mixed and filled in airtight bags to prepare powders.

1-2. Manufacture of tablets

Opuntia extract 10 mg

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

1-3. Preparation of capsules

Opuntia extract 10 mg

Crystalline cellulose 3 mg

Lactose 14.8 mg

Magnesium stearate 0.2 mg

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

1-4. Injection preparation

Opuntia extract 10 mg

180 mg mannitol

Sterile sterilized water for injection 2974 mg

Na ₂ HPO ₄ .2H ₂ O 26 mg

(2 ml) per 1 ampoule in accordance with the usual injection preparation method.

1-5. Liquid  Produce

Lucie extract 20 mg

10 g per isomer

5 g mannitol

Purified water quantity

Each component was added and dissolved in purified water according to the usual liquid preparation method, the lemon flavor was added in an appropriate amount, the above components were mixed, and purified water was added to adjust the whole volume to 100 ml. Then, the solution was filled in a brown bottle and sterilized, .

Formulation example  2. Manufacture of food preparation

1-1. Manufacture of health food

Opuntia extract 100 mg

Vitamin mixture quantity

70 g of vitamin A acetate

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

0.15 mg of vitamin B2

Vitamin B6 0.5 mg

0.2 g of vitamin B12

Vitamin C 10 mg

Biotin 10 g

Nicotinic acid amide 1.7 mg

Folate 50 g

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

Calcium carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

2-2. Health drink  Produce

Opuntia extract 100 mg

Vitamin C 15 g

Vitamin E (powder) 100 g

19.75 g of ferrous lactate

3.5 g of zinc oxide

Nicotinic acid amide 3.5 g

Vitamin A 0.2 g

Vitamin B1 0.25 g

Vitamin B2 0.3g

Water quantification

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The solution thus prepared was filtered and sterilized in a sterilized 2 liter container, It is used in the production of the health beverage composition of the invention.

Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.

Claims (9)

A pharmaceutical composition for preventing or treating constipation, comprising an extract of Galla Rhois as an active ingredient. The pharmaceutical composition for preventing or treating constipation according to claim 1, wherein the extract is extracted with water or an alcohol having 1 to 4 carbon atoms. The pharmaceutical composition for preventing or treating constipation according to claim 1, wherein the extract is a hot-water extract. The method according to claim 1, wherein the constipation is caused by at least one drug selected from the group consisting of a calcium channel blocker, an anticholinergic drug, an analgesic, an antidepressant, an antihistamine, an antispasmodic, an anticonvulsant, an aluminum- &Lt; / RTI &gt; or a pharmaceutically acceptable salt thereof, for the prophylaxis or treatment of constipation. The pharmaceutical composition for preventing or treating constipation according to claim 1, wherein the composition increases the number and weight of bowel movements. The pharmaceutical composition according to claim 1, wherein the composition increases the moisture content of the sides. The pharmaceutical composition for preventing or treating constipation according to claim 1, wherein the composition increases intestinal mucus secretion. A food composition for preventing or ameliorating constipation, comprising a rhizome extract as an active ingredient. delete

Images